BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/14/2018 10:51:22 AM | Browse: 248 | Download: 183
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 42267
Country/Territory South Korea
2018-09-19 05:57
Peer-Review Started
2018-09-19 08:13
To Make the First Decision
2018-10-17 01:44
Return for Revision
2018-10-18 00:40
2018-10-24 14:23
Second Decision
2018-11-23 11:17
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2018-11-26 05:28
Articles in Press
2018-11-26 05:28
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2018-12-06 10:24
Publish the Manuscript Online
2018-12-14 10:51
ISSN 1948-5204 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Clinical Trials Study
Article Title Multicenter phase Ⅱ trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
Manuscript Source Unsolicited Manuscript
All Author List Moon Jae Chung, Huapyong Kang, Ho Gak Kim, Jong Jin Hyun, Jun Kyu Lee, Kwang Hyuck Lee, Myung Hwan Noh, Dae Hwan Kang, Sang Hyub Lee and Seungmin Bang
Author(s) ORCID Number
Moon Jae Chung http://orcid.org/0000-0002-5920-8549
Huapyong Kang http://orcid.org/0000-0003-1790-0809
Ho Gak Kim http://orcid.org/0000-0003-3365-1662
Jong Jin Hyun http://orcid.org/0000-0002-5632-7091
Jun Kyu Lee http://orcid.org/0000-0002-2694-3598
Kwang Hyuck Lee http://orcid.org/0000-0002-2898-6233
Myung Hwan Noh http://orcid.org/0000-0003-3460-2264
Dae Hwan Kang http://orcid.org/0000-0002-7539-0723
Sang Hyub Lee http://orcid.org/0000-0003-2174-9726
Seungmin Bang http://orcid.org/0000-0001-5209-8351
Funding Agency and Grant Number
Corresponding author Seungmin Bang, MD, PhD, Professor, Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, South Korea. bang7028@yuhs.ac
Keywords Pancreatic cancer; FOLFIRINOX; Clinical Trial, Phase Ⅱ; Chemotherapy; Gemcitabine refractory
Core Tip For gemcitabine (GEM)-refractory unresectable pancreatic cancer (PC), there are limited options of second-line chemotherapy regimen. To find new treatment option for GEM-refractory unresectable PC, we conducted a multicenter phase Ⅱ trial, which evaluated the efficacy and safety of uniquely modified FOLFIRINOX with reduced irinotecan and oxaliplatin. In our results, FOLFIRINOX with reduced irinotecan and oxaliplatin showed acceptable toxicity and promising efficacy. With careful observation of treatment-related hematologic toxicities, this chemotherapy regimen is a promising option for patients with GEM-refractory PC after first-line treatment failure.
Publish Date 2018-12-14 10:51
Citation Chung MJ, Kang H, Kim HG, Hyun JJ, Lee JK, Lee KH, Noh MH, Kang DH, Lee SH, Bang S, Pancreatobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer. Multicenter phase Ⅱ trial of modified FOLFIRINOX in gemcitabin-refractory pancreatic cancer. World J Gastrointest Oncol 2018; 10(12): 505-515
Url https://www.wjgnet.com/1948-5204/full/v10/i12/505.htm
DOI https://dx.doi.org/10.4251/wjgo.v10.i12.505
Full Article (PDF) WJGO-10-505.pdf
Full Article (Word) WJGO-10-505.docx
Manuscript File 42267-Review.doc
Answering Reviewers 42267-Answering reviewers.pdf
Audio Core Tip 42267-Audio core tip.mp3
Biostatistics Review Certificate 42267-Biostatistics statement.pdf
Clinical Trial Registration Statement 42267-Clinical trial registration statement.pdf
Conflict-of-Interest Disclosure Form 42267-Conflict-of-interest statement.pdf
Copyright License Agreement 42267-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s) 42267-Informed consent statement.pdf
Institutional Review Board Approval Form or Document 42267-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 42267-Language certificate.pdf
Supplementary Material 42267-Supplementary material.docx
Peer-review Report 42267-Peer-review(s).pdf
Scientific Misconduct Check 42267-Scientific misconduct check.pdf
Scientific Editor Work List 42267-Scientific editor work list.pdf